for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sinovac Biotech Ltd.

SVA.A

Latest Trade

6.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.92

 - 

6.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Sinovac Says Co Has Provided Over 2.5 Bln Doses Of Coronavac Globally As Of Late Dec 2021

Dec 30 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED FIRST HALF OF 2021 FINANCIAL RESULTS.SINOVAC BIOTECH LTD - AS OF LATE DEC 2021, HAS PROVIDED OVER 2.5 BILLION DOSES OF CORONAVAC GLOBALLY.

Sinovac Receives Approval On Sabin Strain Based Inactivated Polio Vaccine (Sipv) To Support Global Polio Endgame Strategy

July 19 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC RECEIVES APPROVAL ON SABIN STRAIN BASED INACTIVATED POLIO VACCINE (SIPV) TO SUPPORT GLOBAL POLIO ENDGAME STRATEGY.SINOVAC BIOTECH - GOT DRUG REGISTRATION APPROVAL FROM NATIONAL MEDICAL PRODUCT ADMINISTRATION OF CHINA FOR SABIN STRAIN BASED INACTIVATED POLIO VACCINE.SINOVAC BIOTECH LTD - VACCINE IS EXPECTED TO BE AVAILABLE ON MARKET BY END OF 2021.

Interim Analysis From Phase 3 Trial Suggests Efficacy Of 2 Doses Of CoronaVac Is 83.5% Against Symptomatic COVID-19- The Lancet

July 8 (Reuters) - :INTERIM ANALYSIS FROM PHASE 3 TRIAL SUGGESTS EFFICACY OF 2 DOSES OF CORONAVAC IS 83.5% AGAINST SYMPTOMATIC COVID19- THE LANCET.CORONAVAC HAS HIGH EFFICACY AGAINST PCR-CONFIRMED SYMPTOMATIC COVID-19 WITH A GOOD SAFETY AND TOLERABILITY PROFILE - THE LANCET. ((Reuters.Briefs@thomsonreuters.com;)).

The Lancet Infectious Diseases Published Data From Sinovac’s Phase I/Ii Study, World’S First Published Study On Clinical Trial Results Of A Covid-19 Vaccine In Healthy Children And Adolescents A

June 30 (Reuters) - Sinovac Biotech Ltd <SVA.O>::THE LANCET INFECTIOUS DISEASES PUBLISHED DATA FROM SINOVAC’S PHASE I/II STUDY, WORLD’S FIRST PUBLISHED STUDY ON CLINICAL TRIAL RESULTS OF A COVID-19 VACCINE IN HEALTHY CHILDREN AND ADOLESCENTS AGED 3 TO 17 YEARS OLD.SINOVAC BIOTECH - FINDINGS INDICATE CORONAVAC WAS SAFE, WELL TOLERATED, INDUCED STRONG ANTIBODY RESPONSE IN CHILDREN, ADOLESCENTS AFTER 2 DOSES.

EMA Starts Rolling Review Of COVID-19 Vaccine (Vero Cell) Inactivated

May 4 (Reuters) - European Medicines Agency::EMA STARTS ROLLING REVIEW OF COVID-19 VACCINE (VERO CELL) INACTIVATED.EMA SAYS ROLLING REVIEW WILL CONTINUE UNTIL ENOUGH EVIDENCE IS AVAILABLE FOR A FORMAL MARKETING AUTHORISATION APPLICATION..EMA - EMA WILL ASSESS THE COMPLIANCE OF COVID-19 VACCINE (VERO CELL) INACTIVATED WITH THE USUAL EU STANDARDS FOR EFFECTIVENESS, SAFETY AND QUALITY..

Sinovac Reports Q4 EPS $0.96

April 22 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED FOURTH QUARTER 2020 FINANCIAL RESULTS AND FILES 2020 ANNUAL REPORT ON FORM 20-F.Q4 NON-GAAP EARNINGS PER SHARE $1.02.Q4 EARNINGS PER SHARE $0.96.Q4 SALES $327.5 MILLION VERSUS $81.1 MILLION.

Pharmaniaga Says Unit Signed Deal With Sinovac For Ready-To-Fill Bulk Product Of COVID-19 Vaccine

Jan 12 (Reuters) - Pharmaniaga Bhd <PHMA.KL>::UNIT ENTERED BINDING TERM SHEET AGREEMENT WITH SINOVAC LIFE SCIENCES.DEAL FOR PURCHASE OF READY-TO-FILL BULK PRODUCT OF COVID-19 VACCINE.SUBSEQUENTLY, SINOVAC LS AND CO WILL ENTER INTO A LOCAL MANUFACTURING DEAL & A TECHNOLOGY & KNOW-HOW LICENSE DEAL.

Sinovac Biotech Shareholder 1Globe Capital Inks Pact With SEC Regarding 13D Form Compliance

Dec 23 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC BIOTECH SHAREHOLDER 1GLOBE CAPITAL LLC REACHED AGREEMENT WITH SEC TO END INVESTIGATION OF ITS 13D FORM COMPLIANCE - STATEMENT.1GLOBE CAPITAL - CO DECIDED TO ACCEPT A SEC SETTLEMENT OFFER, IN WHICH 1GLOBECAP NEITHER ADMITTED NOR DENIED SEC FINDINGS.1GLOBE CAPITAL - CALLS ON ALL STAKEHOLDERS TO SUPPORT SINOVAC'S COVID-19 VACCINE PROGRAM.

CDH Utopia Limited Reports 8.44% Stake In Sinovac Biotech As Of Dec. 22

Dec 22 (Reuters) - CDH Utopia Limited::CDH UTOPIA LIMITED - REPORTS 8.44% STAKE IN SINOVAC BIOTECH AS OF DEC. 22 BASED ON 71.1 MILLION SHARES OUTSTANDING OF SINOVAC AS OF MARCH 31 BEFORE TAKING INTO ACCOUNT ISSUANCE OF EXCHANGE SHARES.

Sinovac Reports Unaudited Third Quarter 2020 Financial Results

Dec 7 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.10.Q3 SALES ROSE 79.4 PERCENT TO $115.5 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up